N.V. GALEEVA

Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan

Сontact:

Galeeva N.V. ― PhD (medicine), Associate Professor of the Department of Infectious Diseases

Address: 49 Butlerov Str., Kazan, Russian Federation, 420012, tel. +7-919-640-16-62, e-mail: Nelli_04@mail.ru

The author examined the effect of antiviral therapy on spontaneous platelet aggregation in 325 patients with chronic hepatitis C who undergo combination therapy with pegylated interferons and ribavirin (patients with the first genotype of the hepatitis C virus) and standard interferons (with the second and third genotypes of the hepatitis C virus). 55 patients with chronic hepatitis C received 3D-therapy (ombitasvir/paritaprevir/ritonavir/dasabuvir). Conditionally all patients were divided into three groups depending on the number of Tr, according to the phases of hemostasis: I ― phase of hypercoagulability (number of Tr>350×10⁹/l); II ― transient phase between hyper and hypocoagulation (number of Tr 350-200×10⁹/l) and III ― hypocoagulation (number of Tr<200×10⁹/l), which included patients with liver cirrhosis of class А according to Child ― Turcotte ― Pugh.

Regardless of the DIC syndrome phase, CHC patients had an increase of Tr aggregation with an increase in its maximum amplitude, especially pronounced in patients in the hypocoagulation phase. Interferon therapy contributed to an increase in Tr aggregation by the 4^th week of treatment, with its subsequent decrease at the 12^th and 24^th weeks of observation in all studied groups. Unlike IFN therapy, drugs (ombitasvir/pyritaprivir/ritonovir/dasabuvir) did not lead to a decrease in the number of Tr. There was a dynamics aimed at normalizing the aggregation function of Tr during the 12-week treatment of DAAs from the initial data to the end of treatment.

Key words: antiviral therapy, spontaneous platelet aggregation, chronic hepatitis C.

(For citation: Galeeva N.V. Antiviral therapy and spontaneous platelet aggregation in patients with chronic hepatitis С. Practical Medicine. 2019. Vol. 17, № 8, P. 34-39)

REFERENCES

1. Morozov Yu.A., Mednikov R.V., Charnaya M.A. Violations of the hemostatic system in liver pathology and their diagnosis. Gemorragicheskie diatezy, trombozy, trombofilii, 2014, no. 1, pp. 162-174 (in Russ.).
2. Krutov I.V., Davydkin I.L., Khayretdinov R.K. Violation of hemostasis in patients with chronic hepatitis and liver cirrhosis of viral etiology (HCV), complicated by thrombocytopenia. Vestnik RUDN, seriya Meditsina, 2010, no. 3, pp. 139-141 (in Russ.).
3. Yagoda A.V., Koroy P.V. Patologiya pecheni i funktsiya trombotsitov (kliniko-patogeneticheskiy analiz) [Liver pathology and platelet function (clinical and pathogenetic analysis)]. Stavropol: StGMA, 2008. 273 p.
4. Sieghart W., Homonecik M., Jilma B. et al. Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronie hepatitis C. Thromb. Haemost, 2006, vol. 95, pp. 260-266.
5. Burnevich E.Z., Nikulkina E.N., Shchanitsyna S.E. Ombitasvir + paritaprevir / ritonavir and dasabuvir + ribaverin — optimal antiviral therapy of chronic hepatitis C with direct-acting drugs. Klinicheskaya farmakologiya i terapiya, 2015, vol. 24, no. 2, pp. 13-20 (in Russ.).
6. Znoyko O.O. Practical aspects of the application of the first interferon-free regimen for the treatment of chronic hepatitis C in Russia — 3D therapy (paritaprevir / ritonavir + ombitasvir + dasabuvir). Infektsionnye bolezni: novosti, mneniya, obuchenie, 2015, no. 3, pp. 96-103 (in Russ.).
7. Maleev V.V., Polyakova A.M., Kravchenko A.V. Narusheniya gemostaza pri infektsionnykh zabolevaniyakh [Hemostasis disorders in infectious diseases]. Moscow: De-Novo, 2005. 160 p.
8. Burnevich E.Z., Shchanitsyna S.E. Antiviral therapy of chronic hepatitis C based on interferon-α: patterns and principles. Klinicheskaya farmakologiya i terapiya, 2016, vol. 25, no. 1, pp. 8-13 (in Russ.).
9. Kozlovskiy V.I., Kovtun O.S., Seroukhova O.P. et al. Research methods and clinical significance of platelet aggregation. Focus on spontaneous aggregation. Vestnik VGMU, 2013, no. 3, pp. 79-91 (in Russ.).
10. Tugushev A.S. Liver cirrhosis and thrombosis. Zaporozhskiy meditsinskiy zhurnal, 2010, vol. 3, no. 12, pp. 78-83 (in Russ.).
11. Friedlander I. et al. A laboratory study of spontaneous platelet aggregation. J. Clin. Path, 1971, no. 24, pp. 323-327.
12. Krause S. et al. Enhanced Spontaneous Platelet Aggregation and red Blood Cell Fragility in Whole Blood Obtained from Patients with Diabetes. Platelets, 1991, no. 2, pp. 203-206.
13. Eldor., E.A. Rachmilewitz The hypercoagulable state in thalassemia. Blood, 2002, vol. 99, no. 1, pp. 36-43.
14. Shchekotov A.P. Markers of endothelial damage and platelet aggregation in chronic hepatitis and liver cirrhosis. Klinitsist, 2012, no. 1, pp. 31-35 (in Russ.).
15. Batyrova A.S., Bakanov M.I., Surkov A.N. Modern views on the hemostatic system in chronic liver diseases (literature review). Klinicheskaya laboratornaya diagnostika, 2015, no. 8, pp. 40-44 (in Russ.).
16. Koroy P.V. The effect of antiviral therapy of chronic viral hepatitis C on platelet count in peripheral blood. Izvestiya vuzov. Severokavkazkiy region. Estestvennye nauki. Spetsvypusk, 2006, pp. 70-72 (in Russ.).
17. Derbala M.F., Al kaabi S.R., El Dweik N.Z. et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a:impact of bilharziasis and fibrosis stage. World J. Gastroenterol, 2006, vol. 35, no. 12, rr. 5692-5698.
18. Mammaev M.N. Dynamics of patient indicators of the cytokine status of patients with chronic viral hepatitis C in the treatment of interferon. Ross. zhurn. gastroenterol., gepatol., koloproktol, 2001, no. 1, pp. 39-43 (in Russ.).
19. Chernyavskiy V.V., Sizenko A.K., Gvozdetskaya V.V. Inflammation in chronic liver diseases and possible approaches to treatment. Gastroenterologіya, 2014, vol. 51, no. 1, pp. 111-116 (in Russ.).